EP1663295A2 - Formulations de peptides stables - Google Patents

Formulations de peptides stables

Info

Publication number
EP1663295A2
EP1663295A2 EP04762796A EP04762796A EP1663295A2 EP 1663295 A2 EP1663295 A2 EP 1663295A2 EP 04762796 A EP04762796 A EP 04762796A EP 04762796 A EP04762796 A EP 04762796A EP 1663295 A2 EP1663295 A2 EP 1663295A2
Authority
EP
European Patent Office
Prior art keywords
glp
val
formulation according
peptide
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04762796A
Other languages
German (de)
English (en)
Inventor
Morten Schlein
Svend Ludvigsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP1663295A2 publication Critical patent/EP1663295A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to the field of pharmaceutical formulations. More specifically the invention pertains to soluble and stable pharmaceutical formulations.
  • Therapeutic peptides are widely used in medical practise. Pharmaceutical compositions of such therapeutic peptides are required to have a shelf life of several years in order to be suitable for common use. However, peptide compositions are inherently unstable due to sensitivity towards chemical and physical degradation. Chemical degradation involves change of covalent bonds, such as oxidation, hydrolysis, racemization or crosslinking. Physical degra- dation involves conformational changes relative to the native structure of the peptide, which may lead to aggregation, precipitation or adsorption to surfaces.
  • Glucagon has been used for decades in medical practise within diabetes and several gluca- gon-like peptides are being developed for various therapeutic indications.
  • the preprogluca- gon gene encodes glucagon as well as glucagon-like peptide 1 (GLP-1 ) and glucagon-like peptide 2 (GLP-2).
  • GLP-1 analogs and derivatives as well as the homologous lizard peptide, exendin-4 are being developed for the treatment of hyperglycemia within type 2 diabetes.
  • GLP-2 are potentially useful in the treatment of gastrointestinal diseases.
  • all these peptides encompassing 29-39 amino acids have a high degree of homology and they share a number of properties, notably their tendency to aggregate and formation of insoluble fibrils.
  • FIG. 1 ThT fluorescence assay of fibril formation in acylated GLP-1 samples.
  • the samples contain 6 mg/ml acylated GLP-1 , 5 ⁇ M ThT dissolved in water and adjusted to the stated pH. Experimental conditions are described in "Examples”. Briefly, the samples were incubated at 40 °C and shaken with 960 rpm in an Ascent Fluoroskan fluorescence plate reader. All data points are from the same experiment (i.e. all samples are from the same microtiterplate) and are means of eight replica and shown with standard deviations as error bars. Furthermore, these values at 20 and 40 hours are tabulated for each sample.
  • FIG. 10 Proton NMR spectrum of acylated GLP-1 with different additives at pH 7.9. N- terminal histidine signals of the imidazol sidechain are observed at approx 7.80 ppm and 7.00 ppm. The linewidth and position reflects the reduced flexibility of the N-terminal. NMR samples were prepared with 6mg/ml acylated GLP-1 at pH 7.9 dissolved in 90%/10% H2O/D2O. NMR spectra were recorded at 600 MHz using a Varian Inova 600 MHz NMR in- strument using 5mm samples tubes. Sample volumes were 800 ul and spectra were measured at 27 degrees Celcius
  • FIG. 12 Schematic representation of the time dependence of ThT fluorescence on fibril formation.
  • the curve is Eq.(1) fitted to theoretically data points.
  • the graphical meaning of lag time and k app are shown.
  • soluble as used herein referring to a formulation means a liquid formulation wherein substantially all of the active ingredient is on a soluble form. Thus soluble formulations typically are optically clear.
  • shelf-stable as used herein referring to a formulation means that the formulation remains suitable for its intended medical use until its expiration date.
  • Parenteral liquid formulations typically must have a long shelf-life due to the distribution and stockpile before the product reaches doctors and patients.
  • shelf-life of liquid parenteral formulations of peptides are more than 1 year, more than 3 years, such as 5 years at the prescribed condition for keeping the product.
  • buffer as used herein means a chemical compound added to a formulation in order to prevent pH from changing over time.
  • salts as used herein means compounds formed, together with water, by reaction of an acid with a metallic base.
  • effective amount as used herein means a dosage which is sufficient to be effec- tive for the treatment of the patient compared with no treatment.
  • terapéuticaally effective concentration means a concentration which renders treatment effective applying volumes of the pharmaceutical formulation which are typical in the art, e.g. 5 mL, 1 mL or lower than 500 ⁇ L.
  • treatment of a disease means the management and care of a pa- tient having developed the disease, condition or disorder. The purpose of treatment is to combat the disease, condition or disorder. Treatment includes the administration of the active compounds to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complications associated with the disease, condition or disorder.
  • GLP glucagon-like peptide
  • GLP-1 glucagon-like peptide 1
  • GLP-2 glucagon-like peptide 2
  • exendins and analogues and derivatives thereof.
  • exendins which are found in the Gila monster are homologous to GLP-1 and also exert an insulinotropic effect. Examples of exendins are exendin-4 and exendin-3.
  • the glucagon-like peptides have the following sequences : 1 5 10 15 20 25 30 35 GLP-1 HAEGT FTSDV SSYLE GQAAK EFIA LVKGR G GLP-2 HADGS FSDE NTILD NLAAR DFI LIQTK ITD Exendin-4 HGEGT FTSDL SKQME EEAVR LFIE LKGG PSSGA PPPS-NH2 Exendin-3 HSDGT FTSDL SKQME EEAVR LFIEW LKNGG PSSGA PPPS-NH2
  • analogue as used herein referring to a peptide means a modified peptide wherein one or more amino acid residues of the peptide have been substituted by other amino acid residues and/or wherein one or more amino acid residues have been deleted from the peptide and/or wherein one or more amino acid residues have been deleted from the peptide and or wherein one or more amino acid residues have been added to the peptide.
  • Arg ⁇ -GLP-I (7-37) or K34R-GLP-1 (7-37) designates a GLP-1 analogue wherein amino acid residues at position 1-6 have been deleted, and the naturally oc- curing lysine at position 34 has been substituted with arginine (standard single letter abbreviation for amino acids used according to IUPAC-IUB nomenclature).
  • derivative as used herein in relation to a parent peptide means a chemically modi- fied parent protein or an analogue thereof, wherein at least one substituent is not present in the parent protein or an analogue thereof, i.e. a parent protein which has been covalently modified. Typical modifications are amides, carbohydrates, alkyl groups, acyl groups, esters, pegylations and the like.
  • An examples of a derivative of GLP-1 (7-37) is Arg 34 , Lys 26 (N ⁇ -( ⁇ - Glu(N ⁇ -hexadecanoyl)))-GLP-1 (7-37).
  • GLP-1 peptide as used herein means GLP-1 (7-37), a GLP-1 analogue, a GLP-1 derivative or a derivative of a GLP-1 analogue.
  • GLP-2 peptide as used herein means GLP-2(1-33), a GLP-2 analogue, a GLP-2 derivative or a derivative of a GLP-2 analogue.
  • exendin-4 peptide as used herein means exendin-4(1-39), an exendin-4 ana- logue, an exendin-4 derivative or a derivative of an exendin-4 analogue.
  • stable exendin-4 compound as used herein means a chemically modified ex- endin-4(1-39), i.e. an analogue or a derivative which exhibits an in vivo plasma elimination half-life of at least 10 hours in man, as determined by the following method.
  • the method for determination of plasma elimination half-life of an exendin-4 compound in man is :
  • the com- pound is dissolved in an isotonic buffer, pH 7.4, PBS or any other suitable buffer.
  • the dose is injected peripherally, preferably in the abdominal or upper thigh. Blood samples for determination of active compound are taken at frequent intervals, and for a sufficient duration to cover the terminal elimination part (e.g.
  • Pre-dose 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 (day 2), 36 (day 2), 48 (day 3), 60 (day 3), 72 (day 4) and 84 (day 4) hours post dose).
  • Determination of the concentration of active compound is performed as described in Wilken et al., Diabetolo- gia 43(51 ):A143, 2000.
  • Derived pharmacokinetic parameteres are calculated from the concentration-time data for each individual subject by use of non-compartmental methods, using the commercially available software WinNonlin Version 2.1 (Pharsight, Cary, NC, USA).
  • the terminal elimination rate constant is estimated by log-linear regression on the terminal log- linear part of the concentration-time curve, and used for calculating the elimination half-life.
  • DPP-IV protected exendin-4 compound as used herein means an exendin-4 compound which has been chemically modified to render said compound resistant to the plasma peptidase dipeptidyl aminopeptidase-4 (DPP-IV).
  • immunomodulated exendin-4 compound as used herein means an exendin-4 compound which is an analogue or a derivative of exendin-4(1-39) having a reduced immune response in humans as compared to exendin-4(1-39).
  • the method for assessing the immune response is to measure the concentration of antibodies reactive to the exendin-4 compound after 4 weeks of treatment of the patient.
  • isoelectric point as used herein means the pH value where the overall net charge of a macromolecule such as a peptide is zero.
  • peptides there may be many charged groups, and at the isoelectric point the sum of all these charges is zero, i.e. the number of negative charges balances the number of positive charges.
  • the isoelectric point of a peptide may be determined by isoelectric focusing or it may be estimated from the sequence of the peptide by computational algorithms known in the art.
  • the present invention relates to a soluble and shelf-stable pharmaceutical formulation
  • a soluble and shelf-stable pharmaceutical formulation comprising a therapeutically effective concentration of a glucagon-like peptide, a pharmaceutically acceptable preservative, a pharmaceutically acceptable tonicity modifier, optionally a pharmaceutically acceptable buffer, and a pH that is in the range from about 7.0 to about 8.0, characterized in that the content of salts is lower than about 5 mM, preferably lower than about 2 mM, even more preferable lower than about 1 mM.
  • the present invention relates to a soluble and shelf-stable pharmaceutical formulation
  • a soluble and shelf-stable pharmaceutical formulation comprising a therapeutically effective concentration of a glucagon-like peptide, a pharmaceutically acceptable preservative, a pharmaceutically acceptable tonicity modifier, and a pH that is in the range from about 7.0 to about 8.0, characterized in that no buffer is present or low concentration of a buffer is present.
  • no buffer is present in the formulation. In another embodiment of the invention substantially no buffer is present in the formulation.
  • a low concentration of buffer is present in the formulation.
  • the concentration of buffer in the formulation is less than about 8 mM, less than about 6 mM, or less than about 4 mM. In another embodiment of the invention the buffer comprises no phosphorous.
  • the buffer is a zwitterion.
  • the buffer is glycyl-glycine.
  • the buffer is histidine or bicine.
  • the tonicity modifier is not a salt.
  • the tonicity modifier is selected from the group consisting of glycerol, mannitol and dimethylsulphone.
  • the formulation has a pH in the range from about 7.4 to about 8.0
  • the formulation has a pH in the range from about 7.6 to about 7.9.
  • the isoelectric point of said glucagon-like peptide is from 3.0 to 7.0, preferably from 4.0 to 6.0.
  • the glucagon-like peptide is GLP-1 , a GLP-1 analogue, a derivative of GLP-1 or a derivative of a GLP-1 analogue.
  • the GLP-1 analogue is selected from the group consisting of Gly 8 -GLP-1(7-36)-amide, Gly 8 -GLP-1 (7-37), Val 8 -GLP-1 (7-36)-amide, Val 8 -GLP- 1 (7-37), Val 8 Asp 22 -GLP-1 (7-36)-amide, Val 8 Asp 22 -GLP-1 (7-37) , Val 8 Glu 22 -GLP-1 (7-36)- amide , Val 8 Glu 22 -GLP-1 (7-37), Val 8 Lys 22 -GLP-1 (7-36)-amide, Val 8 Lys 22 -GLP-1 (7-37), Val 8 Arg 22 -GLP-1 (7-36)-amide, Val 8 Arg 22 -GLP-1 (7-37), VaI 8 His 22 -GLP-1 (7-36)-amide, Val 8 His 22 -GLP-1 (7-37), Va ⁇ Trp ⁇ Glu ⁇ -GLP-l (7-37), Val 8 Glu 22 -GLP-1
  • the derivative of a GLP-1 analogue is Arg 34 , Lys 26 (N ⁇ - ( ⁇ -Glu(N ⁇ -hexadecanoyl)))-GLP-1(7-37).
  • the glucagon-like peptide is GLP-1 , a GLP-1 analogue, a derivative of GLP-1 or a derivative of a GLP-1 analogue and the concentration in the pharmaceutical composition is higher than 1 mg/ml, preferably higher than 2 mg/ml, more preferred higher than 3 mg/ml, even more preferred higher than 5 mg/ml.
  • the concentration of the glucagon-like peptide in the pharmaceutical composition is in the range from about 1 mg/ml to about 25 mg/ml, preferably in the range from about 2 mg/ml to about 15 mg/ml, more preferred in the range from about 3 mg/ml to about 10 mg/ml, even more preferred in the range from about 5 mg/ml to about 8 mg/ml.
  • the glucagon-like peptide is exendin-4, an exendin-4 analogue, a derivative of exendin-4, or a derivative of an exendin-4 analogue.
  • the peptide is exendin-4.
  • the peptide is a stable exendin-4 compound. In another embodiment of the invention the peptide is a DPP-IV protected exendin-4 compound. In another embodiment of the invention the peptide is an immunomodulated exendin-4 compound.
  • the peptide is ZP10, i.e. HGEGT- FTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2.
  • concentration of the glucagon-like peptide is ex- endin-4, an exendin-4 analogue, a derivative of exendin-4, or a derivative of an exendin-4 analogue in the pharmaceutical composition is from about 5//g/mL to about 10mg/mL, from about 5//g/mL to about 5mg/mL, from about 5 ⁇ g/mL to about 5mg/mL, from about 0.1mg/mL to about 3mg/mL, or from about 0.2mg/mL to about 1 mg/mL.
  • the glucagon-like peptide is GLP-2, a GLP-2 analogue, a derivative of GLP-2 or a derivative of a GLP-2 analogue.
  • the glucagon-like peptide is Gly 2 -GLP-2(1-33).
  • the derivative of GLP-2 or a derivative of a GLP-2 analogue has a lysine residue, such as one lysine, wherein a lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine.
  • the derivative of GLP-2 or said derivative of a GLP-2 analogue is an acylated GLP-2 compound.
  • the derivative of a GLP-2 analogue is Arg 30 ,Lys 17 (N ⁇ - (1-propyl-3-amino-hexadecanoyl)) GLP-2 (1-33).
  • the glucagon-like peptide is GLP-2, a GLP-2 analogue, a derivative of GLP-2 or a derivative of a GLP-2 analogue and the concentration of said glucagon-like peptide in the pharmaceutical composition is from 0.1mg/mL to 100mg/mL, from 0.1mg/mL to 25mg/mL, or from 1mg/mL to 25mg/mL.
  • the preservative is selected from phenol, m-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p- hydroxybenzoate, 2-phenylethanol, benzyl alcohol, chlorobutanol, and thiomerosal, or mixtures thereof.
  • the invention in another aspect relates to a method for preparation of a pharmaceutical com- position, comprising dissolving the GLP compound and admixing the preservative and tonicity modifier.
  • the invention in another aspect relates to a pharmaceutical formulation having a pH between about 7.4 to about 8.0, said composition comprising a glucagon-like peptide and at least one pharmaceutically acceptable excipient, wherein said composition is shelf stable as measured in a Thioflavin T assay as described herein which shows less than three fold increase of the Thioflavin T fluorescence from 20 hours to 40 hours during incubation of the sample at 40 °C (based on the mean Thioflavin T fluorescence at each time point).
  • the invention in another aspect relates to a pharmaceutical formulation having a pH between about 7.4 to about 8.0, said composition comprising a glucagon-like peptide and at least one pharmaceutically acceptable excipient, wherein said composition is shelf stable as measured in a Thioflavin T assay as described herein which shows less Thioflavin T fluorescence after storage of the composition for 40 hours at 40 °C than a similar formulation buffered by 8 mM phosphate at the same pH.
  • the present invention relates to a method for the treatment of hyperglyce- mia comprising parenteral administration of an effective amount of the pharmaceutical composition comprising a GLP-1 peptide to a mammal in need of such treatment.
  • the invention relates to a method for the treatment of obesity, beta-cell deficiency, IGT or dyslipideamia comprising parenteral administration of an effective amount of the pharmaceutical composition comprising a GLP-1 peptide to a mammal in need of such treatment.
  • the present invention relates to a method for the treatment of short bowels syndrome comprising the administration of a formulation comprising a GLP-2 compound to a mammal in need of such treatment.
  • excipients such as preservatives, isotonic agents and surfactants in pharmaceutical compositions are well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 19 th edition, 1995.
  • the parent glucagon-like peptide can be produced by peptide synthesis, e.g. solid phase peptide synthesis using t-Boc or F-Moc chemistry or other well established techniques.
  • the parent glucagon-like peptide can also be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the polypeptide and capable of expressing the polypeptide in a suitable nutrient medium under conditions permitting the expression of the peptide, after which the resulting peptide is recovered from the culture.
  • the medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g.
  • the peptide produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the pro- teinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like, dependent on the type of peptide in question.
  • a salt e.g. ammonium sulphate
  • the DNA sequence encoding the parent peptide may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the peptide by hybridisation using synthetic oligonucleotide probes in accordance with standard techniques (see, for example, Sambrook, J, Fritsch, EF and Maniatis, T, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989).
  • the DNA sequence encoding the peptide may also be prepared synthetically by estab- lished standard methods, e.g.
  • the DNA sequence may also be prepared by poly- merase chain reaction using specific primers, for instance as described in US 4,683,202 or Saiki et al., Science 239 (1988), 487 - 491.
  • the DNA sequence may be inserted into any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.
  • the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid.
  • the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
  • the vector is preferably an expression vector in which the DNA sequence encoding the peptide is operably linked to additional segments required for transcription of the DNA, such as a pro- moter.
  • the promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA encoding the peptide of the invention in a variety of host cells are well known in the art, cf. for instance Sambrook et al., supra.
  • the DNA sequence encoding the peptide may also, if necessary, be operably connected to a suitable terminator, polyadenylation signals, transcriptional enhancer sequences, and transla- tional enhancer sequences.
  • the recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
  • the vector may also comprise a selectable marker, e.g. a gene the product of which comple- ments a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kana- mycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.
  • a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector.
  • the secretory signal sequence is joined to the DNA sequence encoding the peptide in the correct reading frame.
  • Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the peptide.
  • the secretory signal sequence may be that normally associated with the peptide or may be from a gene encoding another secreted protein.
  • the host cell into which the DNA sequence or the recombinant vector is introduced may be any cell which is capable of producing the present peptide and includes bacteria, yeast, fungi and higher eukaryotic cells.
  • suitable host cells well known and used in the art are, without limitation, £. coli, Saccharomyces cerevisiae, or mammalian BHK or CHO cell lines.
  • Thioflavin T is such a probe and has a distinct fluorescence signature when binding to fibrils [Naiki et al. (1989) Anal. Biochem. 177, 244-249; LeVine (1999) Methods. Enzymol. 309, 274-284].
  • F is the ThT fluorescence at the time t (see Fig. 12).
  • the constant t 0 is the time needed to reach 50% of maximum fluorescence.
  • Formation of a partially folded intermediate of the peptide is suggested as a general initiating mechanism for fibrillation. Few of those intermediates nucleate to form a template onto which further intermediates may assembly and the fibrillation proceeds.
  • the lag-time corresponds to the interval in which the critical mass of nucleus is built up and the apparent rate constant is the rate with which the fibril itself is formed.
  • acylated GLP-1 The physico-chemical properties of the solvent/solution may affect the degree of self- assembly as well as the flexibility and partial unfolding of acylated GLP-1 molecules, i.e. factors responsible for initiation of amyloid fibril formation.
  • Sample preparation Samples were prepared freshly before each assay. Usually, acylated GLP-1 was dissolved to 6 mg/ml in desired buffer or solvent. The pH of the sample was adjusted to the desired value using appropriate amounts of concentrated NaOH and HCIO 4 . Thioflavin T was added to the samples from a 1 mM stock solution in H 2 O to a final concentration of 5 ⁇ M.
  • Sample aliquots of 100 ⁇ l were placed in a 96 well microtiter plate (Packard Opti- PlateTM-96, white polystyrene). Usually, eight replica of each sample (corresponding to one test condition) was placed in one column of wells. The plate was sealed with Scotch Pad (Qiagen).
  • the measurement points were saved in Microsoft Excel format for further process- ing and curve drawing and fitting was performed using GraphPad Prism.
  • the background emission from ThT in the absence of fibrils was negligible.
  • the data points are typically a mean of eight samples and shown with standard deviation error bars. Only data obtained in the same experiment (i.e. samples on the same plate) are presented in the same graph ensuring a relative measure of fibrillation between experiments.
  • the data set may be fitted to Eq. (1). However, since full sigmodial curves in this case are not usually achieved during the measurement time, the degree of fibrillation is expressed as ThT fluorescence at 20 and 40 hours, calculated as the mean of the eight samples and shown with the standard deviation.
  • the physical stability is always better in water at a given pH compared to phosphate buffer.
  • Using water adjusted to pH7.7 results in similar physical stability as achieved with 8 mM phosphate pH8.15, and in water at pH7.53 the physical stability is comparable with 8 mM phosphate pH7.88. Less tendency to fibril formation is observed when lowering the phosphate concentration at a given pH.
  • the phosphate concentration is gradually lowered from 8 mM phosphate to 1 mM phosphate at pH7.9.
  • 1 mM phosphate buffer, pH7.90 the physical stability is similar to that of an acylated GLP-1 solution in water, pH7.90.
  • zwitterionic buffer substances may be added without compromising the increased physical stability achieved in water in the absence of phosphate ions.
  • Solutions of acylated GLP-1 with 10 mM MOPS or TES are both more physical stable than a solution in 8 mM phosphate at pH8.14, see figure 4, and 10 mM MOBS pH7,9 has similar physical stability as water pH7.9, see figure 5.
  • HEPES or BICINE may be used as buffer at 10 mM without significantly increasing the fibrillation compared to water at pH7.89, see figure 6.
  • acylated GLP-1 are in all cases significantly more physically stable than in aqueous solution with 8 mM phosphate, pH7.92.
  • Buffered aqueous solutions using 10 mM HEPES become slightly more physically unstable when pH is gradually lowered from pH7.9 to pH7.51 , see figure 7.
  • these are still more stable than solutions buffered with phosphate, see figure 6.
  • acylated GLP-1 in 10 mM HEPES pH7.73 is as physically stable as in 8 mM phosphate pH8.15, compare figure 7 with figure 2.
  • Some amino acids may also be used as zwitterionic buffers.
  • an added tonicity modifier must not be an electrolyte/salt. This is illustrated in figure 9, where the addition of 10 mM NaCI to an acylated GLP- 1 solution in water promotes fibrillation. This effect is even more pronounced when adding 100 mM NaCI. However, both concentrations are much lower than the physiological NaCI concentration of 154 mM, usually applied when using NaCI as a tonicity modifier.
  • a skilled artisan in the field of protein NMR spectroscopy will be able to assign most of the resonance peaks of a proton NMR spectrum of a protein to specific protons (or proton groups) in the protein given that the actual behavior of the protein in solution give rise to a well resolved proton NMR spectrum (well known to the skilled artisan in the field).
  • the line width of the resonance peaks in the protein NMR spectrum reflects to some extend the size and dynamic properties of the protein in solution.
  • Aqueous solution of acylated GLP-1 at concentrations between 1 and 30 mg/ml, with or without buffers in the pH range 7.0 to 8.2 give rise to NMR spectra that to a high extend allow the afore mentioned resonance assignment.
  • Narrow proton resonances of the imidazol side chain of the N-terminal histidine is reflecting a higher degree of structural flexibility of the N-terminal part of acylated GLP-1 in so- lution as compared to more broad proton resonances of the imidazol side chain of the N- terminal histidine which reflects that this part of the structure is more rigid and ordered.
  • amide protons of glutamic acid residue 9 and glycine residue 10 of acylated GLP-1 can be separately monitored under the influence of different buffer substances or variation in additives and their concentration under otherwise constant conditions.
  • the exchange rate of amide protons in the pH range 7.0 to 8.2 reflects clearly the degree to which the specific amide protons are protected from direct access to the solvent water molecules.
  • Figure 11 shows that the two mentioned amide proton resonances vary in line width and intensity as buffers or additives are changed. Surprisingly, but very pronounced, is the almost disappearance of amides protons resonances in the NMR spectrum of acylated GLP- 1 in aqueous solution buffered with 8 mM phosphate at pH 7.9 compared to the non-buffered situation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé pour augmenter la durée de conservation d'une formulation pharmaceutique contenant un peptide de type glucagone.
EP04762796A 2003-09-01 2004-08-31 Formulations de peptides stables Withdrawn EP1663295A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301239 2003-09-01
US50115703P 2003-09-08 2003-09-08
PCT/DK2004/000576 WO2005021022A2 (fr) 2003-09-01 2004-08-31 Formulations de peptides stables

Publications (1)

Publication Number Publication Date
EP1663295A2 true EP1663295A2 (fr) 2006-06-07

Family

ID=34276702

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04762796A Withdrawn EP1663295A2 (fr) 2003-09-01 2004-08-31 Formulations de peptides stables

Country Status (3)

Country Link
EP (1) EP1663295A2 (fr)
JP (1) JP5518282B2 (fr)
WO (1) WO2005021022A2 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531988C (fr) 2003-08-05 2016-06-28 Novo Nordisk A/S Nouveaux derives de l'insuline
PL2206495T3 (pl) 2005-01-14 2013-05-31 Camurus Ab Bioadhezyjne formulacje do stosowania miejscowego
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
DE602005026998D1 (de) 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
AU2005325510B2 (en) 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
US8546326B2 (en) 2005-06-06 2013-10-01 Camurus Ab Glp-1 analogue formulations
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
LT3228320T (lt) 2008-10-17 2020-03-10 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
EP2352513B1 (fr) 2008-10-30 2016-09-14 Novo Nordisk A/S Traitement du diabète à l'aide d'injections d'insuline avec une fréquence inférieure à une injection par jour
US9060098B2 (en) 2009-01-16 2015-06-16 Broadcom Corporation Method and system for data processing in a device with integrated set-top-box and femtocell functionality
US8903364B2 (en) 2009-01-16 2014-12-02 Broadcom Corporation Method and system for processing and delivery of multimedia content by an integrated femtocell and set-top-box device
US20100210239A1 (en) 2009-02-17 2010-08-19 Jeyhan Karaoguz Service mobility via a femtocell infrastructure
US9049652B2 (en) 2009-02-27 2015-06-02 Broadcom Corporation Method and system for controlling access and utilization of femtocells via a network based service
US8855048B2 (en) 2009-02-27 2014-10-07 Broadcom Corporation Method and system for peer-to-peer cellular communications
US8259617B2 (en) 2009-03-18 2012-09-04 Broadcom Corporation Method and system for timely delivery of multimedia content via a femtocell
US20120231022A1 (en) 2009-05-28 2012-09-13 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
WO2011056713A2 (fr) 2009-11-03 2011-05-12 Amylin Pharmaceuticals, Inc. Composés agonistes du récepteur du glp-1 pour traiter l'apnée obstructive du sommeil
PL2498802T3 (pl) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
EP2498801B1 (fr) 2009-11-13 2018-01-24 Sanofi-Aventis Deutschland GmbH COMPOSITION PHARMACEUTIQUE COMPRENANT desPro36Exendin-4(1-39)-Lys6-NH2 ET DE LA MÉTHIONINE
DE102010011919A1 (de) 2010-03-18 2011-09-22 Sanofi-Aventis Deutschland Gmbh Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
SI2611458T1 (sl) 2010-08-30 2017-01-31 Sanofi-Aventis Deutschland Gmbh Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
HRP20191793T1 (hr) 2010-10-27 2019-12-27 Novo Nordisk A/S Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja
WO2012088157A2 (fr) 2010-12-22 2012-06-28 Amylin Pharmaceuticals, Inc. Agonistes du récepteur de glp-1 pour une transplantation de cellules d'îlot
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
HUE027989T2 (en) 2011-08-29 2016-11-28 Sanofi Aventis Deutschland A pharmaceutical composition for use in glycemic control in patients with type 2 diabetes
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
SG11201407678YA (en) 2012-05-25 2014-12-30 Camurus Ab Somatostatin receptor agonist formulations
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
LT2934567T (lt) 2012-12-21 2018-09-10 Sanofi Eksendino-4 dariniai kaip dvigubi glp1/gip arba trigubi glp1/gip/gliukagono agonistai
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
EP2991672A1 (fr) 2013-04-30 2016-03-09 Novo Nordisk A/S Schéma d'administration d'un nouveau type
EP3080150B1 (fr) 2013-12-13 2018-08-01 Sanofi Analogues peptidiques d'exendine-4 en tant qu'agonistes du récepteur gip/glp-1 double
WO2015086730A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4 non acylés
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080154B1 (fr) 2013-12-13 2018-02-07 Sanofi Agonistes doubles du récepteur glp-1/gip
CA2932875A1 (fr) 2014-01-09 2015-07-16 Sanofi Formulations pharmaceutiques stabilisees sans glycerol d'analogues de l'insuline et/ou de derives de l'insuline
AU2015205620A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin aspart
EP3091995B1 (fr) 2014-01-09 2024-03-20 Sanofi Formulations pharmaceutiques stabilisées d'insuline aspart
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CA2970200A1 (fr) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Formulation contenant un rapport fixe d'insuline glargine/lixisenatide
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
MY197023A (en) 2015-12-23 2023-05-22 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
PE20200013A1 (es) 2017-06-20 2020-01-06 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
MA49459A (fr) 2017-06-21 2020-04-29 Amgen Inc Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2020026471A1 (fr) * 2018-07-31 2020-02-06 株式会社親広産業 Promoteur de la consommation de glucose et promoteur de glycolyse
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2021009027A1 (fr) 2019-07-12 2021-01-21 Novo Nordisk A/S Formulation d'insuline à concentration élevée
GB201917723D0 (en) * 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
JP2024501467A (ja) * 2020-12-11 2024-01-12 アイピー２アイピーオー イノベ－ションズ リミテッド 新規化合物
MX2023006281A (es) * 2020-12-16 2023-06-13 Zealand Pharma As Composicion farmaceutica de agonistas duales de glp-1/glp-2.
WO2022140373A1 (fr) * 2020-12-22 2022-06-30 Eli Lilly And Company Formulations peptidiques thérapeutiques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
DE122007000001I1 (de) * 1999-01-14 2007-06-28 Amylin Pharmaceuticals Inc Neue exendin agonist Formulierungen und deren Verabreichung
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US7199217B2 (en) * 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
US7259233B2 (en) * 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
PT1412384E (pt) * 2001-06-28 2008-03-28 Novo Nordisk As Formulação estável de glp-1 modificado
EP1631308B1 (fr) * 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Nouveaux procedes et nouvelles compositions pour une administration amelioree par voie muqueuse de peptides et de proteines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005021022A2 *

Also Published As

Publication number Publication date
WO2005021022A3 (fr) 2005-06-30
JP5518282B2 (ja) 2014-06-11
JP2007504178A (ja) 2007-03-01
WO2005021022A2 (fr) 2005-03-10

Similar Documents

Publication Publication Date Title
US20100190715A1 (en) Stable Formulations of Peptides
EP1663295A2 (fr) Formulations de peptides stables
CN102940879B (zh) 稳定化的药物肽组合物
CN1812808B (zh) 稳定化的药物肽组合物
CN104667264B (zh) 包含胰岛素、烟酰胺和氨基酸的制剂
JP6581606B2 (ja) 選択的グルカゴン受容体アゴニストとしてのエキセンジン−４誘導体
JP5241849B2 (ja) インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
AU2004243531B2 (en) Stabilized pharmaceutical peptide compositions
US8114959B2 (en) Stabilized pharmaceutical peptide compositions
JP5248113B2 (ja) ペプチドの安定な処方
US8748376B2 (en) Stable formulations of peptides
JP6391589B2 (ja) 官能基化されたエキセンディン−４誘導体
US7595293B2 (en) Stable pharmaceutical compositions
TW201625669A (zh) 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
JP7499305B2 (ja) アシル化ｇｌｐ－１誘導体
KR20150002777A (ko) 인슐린 제제
EP4121003B1 (fr) Formulations liquides d'analogues de glucagon

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060403

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20110920

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20151104